SEHK:2162
SEHK:2162Biotechs

Why Is Keymed Biosciences (SEHK:2162) Drawing Big-Name Support After Stapokibart’s Approval in China?

Goldman Sachs recently initiated coverage on Keymed Biosciences, highlighting the approval of its first commercial product, stapokibart, in China for atopic dermatitis and chronic rhinosinusitis, while expressing confidence in the pipeline asset CM512 for asthma and COPD. This development underscores the growing recognition of Keymed's product pipeline and the confidence major institutions are placing in the company's future prospects. We'll explore how optimism for Keymed's pipeline,...